No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group | Zendy

Tamara Castaño-Bonilla | Zendy; Eva Barragán | Zendy; Claudia Sargas | Zendy; Alejandro Sanz | Zendy; Lorenzo Algarra | Zendy; Pilar HerreraPuente | Zendy; Raimundo GarcíaBoyero | Zendy; Manuel Barrios | Zendy; David MartínezCuadrón | Zendy; Rebeca RodríguezVeiga | Zendy; Blanca Boluda | Zendy; Cristina Gil | Zendy; Josefina SerranoLópez | Zendy; Joaquín MartínezLópez | Zendy; María José Sayas-Lloris | Zendy; María Teresa Olave | Zendy; Rosalía RiazaGrau | Zendy; Teresa Bernal-Del Castillo | Zendy; María José Larráyoz | Zendy; Raquel Amigo | Zendy; Antonio JiménezVelasco | Zendy; Joaquín Sánchez | Zendy; Rosa Ayala | Zendy; Carlos Blas | Zendy; Daniel LáinezGonzález | Zendy; Juana SerranoLópez | Zendy; Miguel Á. Sanz | Zendy; Juan Manuel AlonsoDomínguez | Zendy; Pau Montesinos | Zendy

Open Access

No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group

Author(s) -

Tamara Castaño-Bonilla,

Eva Barragán,

Claudia Sargas,

Alejandro Sanz,

Lorenzo Algarra,

Pilar HerreraPuente,

Raimundo GarcíaBoyero,

Manuel Barrios,

David MartínezCuadrón,

Rebeca RodríguezVeiga,

Blanca Boluda,

Cristina Gil,

Josefina SerranoLópez,

Joaquín MartínezLópez,

María José Sayas-Lloris,

María Teresa Olave,

Rosalía RiazaGrau,

Teresa Bernal-Del Castillo,

María José Larráyoz,

Raquel Amigo,

Antonio JiménezVelasco,

Joaquín Sánchez,

Rosa Ayala,

Carlos Blas,

Daniel LáinezGonzález,

Juana SerranoLópez,

Miguel Á. Sanz,

Juan Manuel AlonsoDomínguez,

Pau Montesinos

Publication year - 2022

Publication title -

disease markers

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.912

H-Index - 66

eISSN - 1875-8630

pISSN - 0278-0240

DOI - 10.1155/2022/3132941

Subject(s) - gemtuzumab ozogamicin , medicine , myeloid leukemia , calicheamicin , oncology , cohort , univariate analysis , proportional hazards model , cd33 , genotype , survival analysis , multivariate analysis , stem cell , biology , genetics , cd34 , gene , biochemistry

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research